JWH-073

# Research Output: JWH-073

## Chemical Identity

**Verified from PubChem (CID 10471670) [Ref 37]:**

- **Systematic/IUPAC name:** (1-butylindol-3-yl)-naphthalen-1-ylmethanone
- **Also known as:** (1-butyl-1H-indol-3-yl)(naphthalen-1-yl)methanone; 1-butyl-3-(1-naphthoyl)indole
- **CAS Number:** 208987-48-8 [Ref 37]
- **PubChem CID:** 10471670
- **Molecular formula:** C23H21NO
- **Molecular weight:** 327.4 g/mol
- **InChIKey:** VCHHHSMPMLNVGS-UHFFFAOYSA-N
- **SMILES:** CCCCn1cc(C(=O)c2cccc3ccccc23)c4ccccc14 [Ref 37]
- **Chemical class:** Naphthoylindole (aminoalkylindole subclass)
- **Stereochemistry:** Achiral molecule; no stereocenters

**Comparison to brief seed data:**
The brief lists no PubChem CID, SMILES, formula, or InChIKey — all of these are now confirmed above and should be populated. The systematic name matches. The molecular weight (327.4 g/mol) is confirmed. Physical properties (melting point, solubility) were not retrievable from public databases or supplier pages during this research session; these are not in the published literature for JWH-073 specifically.

---

## Pharmacology

### Receptor Binding Affinity

JWH-073 is a potent cannabinoid receptor agonist with nanomolar affinity at both CB1 and CB2 receptors [Ref 35]:

- **CB1 receptor:** Ki = 8.9 ± 1.8 nM (range 8.9–12.9 nM across different assay conditions) [Ref 35]
- **CB2 receptor:** Ki = 38 ± 24 nM [Ref 35]
- **CB1:CB2 selectivity ratio:** ~0.23 (approximately 4–5× more selective for CB1 than CB2)

For comparison, Δ9-THC has CB1 Ki ~35–53 nM and CB2 Ki ~75 nM; JWH-073 is substantially more potent at CB1 than THC. JWH-073 has ~50% of the in vivo potency of JWH-018, which bears a pentyl (vs butyl) N-linked chain. Computational modeling confirms that shorter N-linked alkyl chains predict lower CB1 binding affinity — hence JWH-073 < JWH-018 potency (Chaturvedi et al. 2024 [Ref 32]).

**⚠️ FLAG — Partial vs. Full Agonist Discrepancy:**
The brief characterizes JWH-073 as a "Cannabinoid CB1 receptor partial agonist." However, Brents et al. (2012 [Ref 5]) explicitly state that "JWH-073 displays equivalent efficacy to that of the CB1R full agonist CP-55,940" in [35S]GTPγS binding assays using mouse brain homogenates. Web sources (citing pharmacological suppliers referencing the original Huffman literature) also characterize JWH-073 as a full agonist at both CB1 and CB2 [Ref 35]. Ossato et al. (2016 [Ref 2]) similarly describe it as an "agonist with nanomolar affinity at CB1 and CB2 receptors." The "partial agonist" classification in the seed data appears to be incorrect based on published primary research. **This discrepancy should be reviewed by an editor — the current evidence supports full agonist classification at CB1.**

### Mechanism of Action

JWH-073 activates CB1 and CB2 receptors as a Gi/Go-coupled agonist, producing:
- Inhibition of adenylyl cyclase → reduced intracellular cAMP [Ref 4]
- Activation of G-protein (GTPγS binding) [Ref 5]
- Modulation of ion channels (K+ and Ca2+) at CB1R
- Dose-dependent stimulation of dopamine release in the nucleus accumbens (mesolimbic pathway), blocked by CB1R antagonist AM251 [Ref 2]
- Suppression of hippocampal long-term potentiation (LTP) by ~60% in vitro [Ref 1]
- EEG desynchronization: suppression of α (~23%), γ (~26%), and β (~26%) bands in somatosensory cortex; suppression of all EEG bands in hippocampus within 10 min–2 h after administration (Barbieri et al. 2022 [Ref 1])

Key CB1 receptor binding residues: Phe170, Phe174, Phe177, Phe200, Phe268, and Trp279 via hydrophobic interactions (Chaturvedi et al. 2024 [Ref 32]).

Beta-arrestin2 does not appear to differentially regulate JWH-073 at CB1R (unlike THC, which shows altered sensitivity in beta-arrestin2 knockout mice — JWH-073 did not; Breivogel et al. 2008 [Ref 8]).

### Pharmacokinetics

**Route:** Primarily smoked (inhaled). No published oral bioavailability data for JWH-073 specifically.

**Onset:** Rapid after smoking — effects begin within minutes (consistent with other inhaled cannabinoids; no published Tmax data for JWH-073 in humans).

**Blood kinetics:** No published controlled human pharmacokinetic study for JWH-073. A methodology paper (Cooper et al. 2018 [Ref 29]) developed validated concentration-consistent JWH-073 cigarettes for future controlled human studies; plasma stability was confirmed at −4°C to −80°C up to 1 month. In mice, JWH-073 was confirmed in serum at doses 0.1–5 mg/kg (Uttl et al. 2018 [Ref 30]).

**Parent compound:** Rapidly cleared from blood; parent compound is typically undetectable within 24 h in most biological specimens, consistent with extensive first-pass metabolism (class inference; no JWH-073-specific human data).

**Phase I metabolism:** Extensive hydroxylation producing monohydroxylated metabolites at the N-butyl chain and indole ring [Ref 5]:
- **M1** (N-4-hydroxybutyl): retains CB1R nanomolar affinity; CB1R partial agonist; agonist activity in vivo
- **M3** (various hydroxylation): micromolar CB1R affinity; partial agonist
- **M4** (N-3-hydroxybutyl): retains nanomolar affinity; acts as CB1R **neutral antagonist** (Kb ~40 nM); attenuates cannabinoid-induced hypothermia in vivo — does NOT block locomotion, catalepsy, or analgesia
- **M5** (omega-OH / N-1-hydroxybutyl): retains CB1R affinity; partial agonist; also binds CB2 with high affinity and produces equipotent AC inhibition to parent [Ref 4]
- **M6** (carboxylic acid / N-butanoic acid): does NOT bind CB1R; primary urinary marker

CYP2C9 is implicated in indole ring hydroxylation (absent in zebrafish, explaining metabolic differences in that model; Sardela et al. 2018 [Ref in search]).

**Phase II metabolism:** Glucuronide conjugation by UGT1A1, UGT1A3, UGT1A9, UGT1A10, and UGT2B7 (Chimalakonda et al. 2011 [Ref 27]). Km for hydroxylated K2 metabolites ranged 12–18 µM in human liver and intestinal microsomes. UGTs exhibit high metabolic capacity, suggesting rapid glucuronidation and elimination.

**Urinary detection:**
- Metabolites excreted primarily as glucuronide conjugates [Ref 27]
- JWH-073-COOH (carboxylic acid metabolite): detectable 11–25 days (mean 19 days) in urine after cessation of use (Hegstad et al. 2015 [Ref 31])
- Creatinine-normalized elimination half-life for JWH-073-COOH: **9.3 days** (range 3.6–16.8 days) [Ref 31]

**⚠️ FLAG — Seed Data Half-Life Discrepancy:**
The brief's tolerance section lists "Half-life: 5 days." This appears to conflict with published elimination data. The urinary metabolite half-life is 9.3 days (Hegstad 2015 [Ref 31]), and detection can extend >3 weeks. If "5 days" refers to tolerance half-life (time for CB1R to restore normal sensitivity), this value is not sourced and should be reviewed. No published tolerance reset data exists specifically for JWH-073; the "5 day" tolerance half-life appears inferred from the cannabinoid class. Editorial review recommended.

---

## History

### Discovery and Synthesis

JWH-073 was synthesized by **John William Huffman** (the "JWH" prefix is his initials), an organic chemist at Clemson University, South Carolina [Ref 36]. Beginning approximately in 1984, Huffman's laboratory — funded by the National Institute on Drug Abuse (NIDA) — systematically synthesized over 400 synthetic cannabinoid compounds as pharmacological tools for studying the endocannabinoid system and cannabinoid receptor biology [Ref 36].

JWH-073 is the N-**butyl** homolog of JWH-018 (which bears an N-**pentyl** chain). The shorter butyl chain results in lower CB1 binding affinity and approximately 50% the in vivo potency of JWH-018 [Ref 35]. The synthesis was published in the academic literature as part of Huffman's broader structure-activity relationship studies on 1-alkyl-3-(1-naphthoyl)indoles (Huffman et al. 2005 [Ref 18]; Wiley et al. 2014 [Ref 23]).

No specific publication records the first synthesis date of JWH-073 precisely; it is part of the pre-2005 naphthoylindole research program. JWH-073 was originally developed as a research tool, not a recreational drug.

### Market Emergence

JWH-073 first appeared in illicit herbal smoking blends ("Spice," "K2") in **February 2009**, following Germany's legal scheduling of JWH-018 and CP-47,497-C8 homologs in December 2008 (Dresen et al. 2010 [Ref 16]). Manufacturers rapidly reformulated products, substituting JWH-073 for the newly banned JWH-018. The Austrian EMCDDA reporting in July 2010 identified JWH-073 in a branded product called 'Topaz' — one of the first formal EU notifications for JWH-073.

### Regulatory/Prohibition Timeline

- **December 2008:** JWH-018 and CP-47,497 banned in Germany; JWH-073 appears as replacement
- **December 2009 (~):** UK bans JWH-073 under the Misuse of Drugs Act via generic 3-(1-naphthoyl)indole definition, Class B [Ref 26]
- **March 1, 2011:** US DEA temporarily places JWH-073 in Schedule I (76 FR 11075), along with JWH-018, JWH-200, CP-47,497, and cannabicyclohexanol, as an "imminent hazard to public safety" [Ref 24]
- **March 2012:** US DEA permanently schedules JWH-073 in Schedule I under the Controlled Substances Act [Ref 25]
- **July 2011:** Australia bans JWH-073 as a Schedule 9 prohibited substance under the Poisons Standard [Ref 26]
- **Ongoing:** Canada lists JWH-073 explicitly in the Controlled Drugs and Substances Act [Ref 26]

---

## Subjective Effects

**Published controlled human data:** None. No controlled human pharmacodynamic or subjective-effects study for JWH-073 has been published. A methodology paper (Cooper et al. 2018 [Ref 29]) established validated protocols for future human trials but pharmacodynamic results are not yet published.

**User report data:** Very sparse — only 4 published experience reports exist on Erowid for JWH-073, compared to hundreds for cannabis/THC. This paucity of user-report data is notable. Descriptions from these limited reports note cannabis-like euphoria, relaxation, and altered sensory perception, with effects considered similar to but potentially shorter-lasting than JWH-018.

**Inferred from case reports and animal research:**

**Desired/common effects (class-based inference with some case report support):**
- Euphoria, relaxation, and mood elevation (cannabis-like) [Ref 20, Ref 12]
- Appetite enhancement [Ref 14]
- Pain suppression / analgesia (documented in multiple animal models [Ref 2])
- Altered sensory perception [Ref 11]
- Sedation, motor suppression [Ref 1]
- Time distortion [class inference]
- Thought connectivity and altered cognition [class inference; Ref 1 shows memory impairment]

**Adverse/adverse-associated effects (from case reports and animal studies):**
- Tachycardia and cardiovascular effects [Ref 10, Ref 13]
- Agitation and restlessness [Ref 13]
- Paranoia and anxiety [Ref 11, Ref 13]
- Hallucinations — visual and auditory [Ref 27, Ref 11]
- Delusions [Ref 11]
- Nausea and vomiting [Ref 15]
- Seizures (myoclonia, tonic-clonic) — documented in animal studies and case reports [Ref 2, Ref 11]
- Confusion and cognitive impairment [Ref 1]
- Acute psychosis [Ref 13]
- Memory impairment lasting up to 24 h post-exposure [Ref 1]
- EEG perturbation persisting at 24 h [Ref 1]

**Animal-study-derived effects (Ossato et al. 2016 [Ref 2]; Barbieri et al. 2022 [Ref 1]):**
- Hypothermia
- Catalepsy
- Reduced motor activity (transient, up to 25 min at 1 mg/kg in mice)
- Visual sensorimotor impairment (up to 105 min)
- Seizures, myoclonia, hyperreflexia, aggression at higher doses
- Stimulation of mesolimbic dopamine transmission (dose-dependent)
- All behavioral effects blocked by CB1R antagonist AM251 → fully CB1R-mediated

**Duration (seed data, not independently sourced):**
The brief lists onset 5–10 min, peak 60–90 min, offset 5–10 min, aftereffects 60–90 min, total 1–2 hours (smoked). These values are plausible given the inhaled route and cannabinoid pharmacology but are **not confirmed by published human pharmacokinetic studies** for JWH-073. They are consistent with reports of JWH-073 producing shorter effects than JWH-018 (due to the butyl vs pentyl chain difference), but no comparative controlled data exists. **Flag for editorial review.**

---

## Safety & Toxicity

### Acute Toxicity

No LD50 data published for JWH-073 in animals or humans. No therapeutic index is established. The brief notes "Acute: low; Chronic: low — inferred from pharmacological class." This requires editorial review, as JWH-073 is not pharmacologically identical to cannabis (it is a full CB1 agonist with active pharmacologically active metabolites, and clinical data show more severe adverse effects than cannabis at equivalent subjective doses).

### In Vitro Cytotoxicity

Koller et al. (2013 [Ref 7]) found:
- JWH-073 induced membrane damage in buccal (TR146) and breast (MCF-7) cells at concentrations ≥75–100 µM
- DNA migration (genotoxicity) in buccal cells and liver cells (HepG2) in single-cell gel electrophoresis assays
- Anti-estrogenic effects at 2.1–23.0 µM
- No impact on cytokine release (IL-10, IL-6, IL-12, TNFα) in human PBMCs
- Authors note: "All toxic effects were observed with concentrations higher than those expected in body fluids of users" — but acknowledge genotoxic effects may be relevant at epithelial exposure levels

### Clinical Case Reports and Adverse Events

1. **Young et al. (2012 [Ref 10]):** 17-year-old with chest pain, tachycardia followed by bradycardia after smoking K9; JWH-018 AND JWH-073 confirmed on laboratory analysis. First laboratory-confirmed cardiotoxicity case documenting JWH-073.

2. **Simmons et al. (2011 [Ref 11]):** Three cases with urinary JWH-073 metabolites confirmed:
   - Case 1: Seizure, tachycardia, acidosis, unresponsiveness (responded to benzodiazepines)
   - Case 2: Unresponsive, hypertension, agitation, GCS 7 → intubated; recovered after 24 h
   - Case 3: Paranoia and delusions; discharged after observation

3. **Hermanns-Clausen et al. (2013 [Ref 13]):** Retrospective study of 29 SC-exposed emergency patients; JWH-073 detected in blood from one patient. Common findings across SC group: tachycardia, agitation, hallucination, hypertension, blood glucose elevation, hypokalemia, vomiting. Severe findings: chest pain, seizures, myoclonia, acute psychosis.

4. **Patton et al. (2013 [Ref 9]):** Fatal case: 23-year-old found with self-inflicted lethal neck wound after SC use; trace JWH-073 found in smoke residue. Demonstrates potential for extreme psychiatric decompensation with SC products.

5. **Sherpa et al. (2015 [Ref 34]):** SC use associated with STEMI, subarachnoid hemorrhage, reversible cardiomyopathy, acute rhabdomyolysis, and severe metabolic derangements in a single patient.

### Population-Level Safety Data

Tait et al. (2015 [Ref 15]) systematic review of ~4,000 SC cases identified:
- **Most common:** Tachycardia (37–77%), agitation (16–41%), nausea (13–94%)
- **Typical course:** Resolved with symptomatic care (IV fluids, benzodiazepines, anti-emetics); length of stay <8 hours
- **Serious adverse events:** Myocardial infarction, ischemic stroke, emboli, acute kidney injury, generalized tonic-clonic seizures, first-episode psychosis, paranoia, self-harm/suicide ideation, hyperemesis, rhabdomyolysis
- **Deaths:** At least 26 documented across the case series
- Note: These data cover the broader SC class; JWH-073-specific incidence rates cannot be extracted.

### Psychotomimetic Risk

Van Amsterdam et al. (2015 [Ref 17]): SCRAs are full agonists (supporting [Ref 5] finding for JWH-073) and more potent than THC. Absence of CBD in SC products removes a potential psychosis moderating factor. Psychosis-like conditions occur more frequently with SCRAs than with natural cannabis, particularly in inexperienced users and those with underlying vulnerability.

---

## Harm Reduction

### Testing and Identification
- JWH-073 is **not detected** by standard immunoassay urine drug screens for cannabis/THC
- Specialized LC-MS/MS testing can detect JWH-073 metabolites (especially JWH-073-COOH) for up to 11–25 days post-use [Ref 31]
- The parent compound is undetectable in blood within ~24 h of use
- Reagent colorimetric testing: Presumptive testing kits exist for identification of substance in preparations, but colorimetric tests have limited specificity for individual SCs

### Emergency Response
- No specific antidote exists for JWH-073 or other synthetic cannabinoids [Ref 14]
- Treatment is supportive and symptomatic:
  - **Agitation/anxiety/seizures:** Benzodiazepines (e.g., lorazepam, diazepam) [Ref 15]
  - **Nausea/vomiting:** Anti-emetics [Ref 15]
  - **Hypotension/dehydration:** IV fluids [Ref 15]
  - **Psychosis:** Atypical antipsychotics (quetiapine reported) [Ref 19]
  - Rimonabant (CB1 antagonist) is not clinically available
- Most presentations resolve within 8 h with supportive care [Ref 15]
- Severe presentations (seizure, AKI, cardiac events) may require intensive care

### Contraindications
- Known history of psychosis or schizophrenia (markedly elevated risk of acute psychosis) [Ref 17]
- History of cardiac arrhythmia (documented cardiotoxicity risk) [Ref 10]
- Use in combination with other sympathomimetic substances (additive cardiovascular burden)
- Adolescent or young adult use associated with greater risk [Ref 13]
- No published pregnancy or breastfeeding data for JWH-073

### Product Variability
The composition of Spice/K2 products is unpredictable — manufacturers frequently reformulate without disclosure. Users purchasing herbal blends labeled as JWH-073 cannot verify actual compound identity or concentration (Dresen et al. 2010 [Ref 16]). Synergistic interactions with co-administered SCs (e.g., JWH-018 + JWH-073) have been documented and can potentiate adverse effects (Brents et al. 2013 [Ref 3]).

---

## Tolerance & Dependence

### Tolerance
CB1 receptor tolerance develops via two mechanisms:
1. **Receptor desensitization:** G-protein-coupled receptor kinase (GRK) phosphorylation → β-arrestin recruitment → receptor uncoupling from G-proteins
2. **Receptor downregulation:** Internalization and reduced receptor surface expression (region-specific; pronounced in neocortex and hippocampus)

These mechanisms are shared across the cannabinoid class. JWH-073 is a full CB1R agonist [Ref 5], and full agonists (vs. partial agonists) generally produce more profound and faster-developing tolerance via greater β-arrestin recruitment [Ref 6].

Cross-tolerance exists between JWH-073 and other cannabinoids (including THC) due to shared CB1R mechanism. No JWH-073-specific tolerance data published (animal or human).

**⚠️ FLAG — Seed Data Half-Life (Tolerance):**
The brief lists tolerance half-life as "5 days" and full reset "1.5 weeks." These values appear plausible for the cannabinoid class (CB1R recovery after chronic exposure is estimated at days to 2+ weeks in animal studies) but are **not sourced to published JWH-073-specific literature.** They represent class-level inferences.

### Dependence and Withdrawal
Dependence on JWH-073 and related SCs is well-documented in clinical literature (Cooper 2016 [Ref 19]; Gunderson et al. 2012 [Ref 20]; Tait et al. 2015 [Ref 15]):
- Daily use leading to physical and psychological dependence has been reported
- Withdrawal symptoms appear consistent with cannabis withdrawal but potentially more severe
- Withdrawal has not been systematically characterized for JWH-073 specifically
- Some symptom relief from benzodiazepines (for agitation) and quetiapine (for psychosis) reported [Ref 19]
- Users may substitute SC products to manage cannabis withdrawal symptoms [Ref 20]

The seed data's "moderate" physical and psychological dependence classification is consistent with published clinical descriptions, though "moderate" may understate the risk for daily or heavy users.

---

## Interactions

**Published drug interaction data:**

1. **JWH-073 + JWH-018 (synthetic cannabinoid combinations):** Brents et al. (2013 [Ref 3]) demonstrated that drug-drug interactions between JWH-018 and JWH-073 are **synergistic** in the Δ9-THC discrimination assay (1:3 and 1:1 dose ratios) and for analgesia (1:1 and 2:3 ratios). Hypothermia was additive at both ratios. Task disruption was **subadditive** at 1:3. Synergy in the competition receptor-binding assay at 1:5 and 1:10 ratios suggests **multiple CB1R-SCB binding sites.** Combinations can "increase the relative potency of marijuana substitutes for subjective Δ9-THC-like effects."

2. **JWH-073 + JWH-250:** Co-administration of sub-threshold doses synergistically impaired visual sensorimotor responses and stimulated mesolimbic DA transmission (Ossato et al. 2016 [Ref 2]).

**Interactions listed in seed data (all "unknown"):** Cocaine, DMT, LSD, Mescaline
- No published data found for any of these combinations with JWH-073 specifically
- **Cocaine:** Both cocaine and SCs promote dopamine release in nucleus accumbens; additive sympathomimetic effects (tachycardia, hypertension) are pharmacologically plausible but unstudied
- **LSD/Mescaline (serotonergic psychedelics):** No interaction data; concurrent use could potentiate psychotomimetic effects; no published data
- **DMT:** No interaction data identified

**CYP interactions:**
JWH-073 is metabolized by CYP enzymes (primarily CYP2C9 for indole ring hydroxylation). CYP2C9 inhibitors (e.g., fluconazole, amiodarone) could theoretically increase parent compound exposure; CYP2C9 inducers (e.g., rifampin) could reduce it. No clinical data exist.

**Serotonin syndrome:** No published evidence of serotonin syndrome risk with JWH-073 specifically. Cannabinoid receptors are distinct from 5-HT receptors; however, some SCs show nonspecific CNS interactions. No formal risk assessment available.

---

## Legal Status

| Jurisdiction | Status | Schedule/Class | Effective Date |
|---|---|---|---|
| United States | Controlled substance | DEA Schedule I | Temp: March 1, 2011; Perm: March 2012 |
| United Kingdom | Controlled substance | Class B, Misuse of Drugs Act | ~December 2009 (generic naphthoylindole definition) |
| Australia | Prohibited substance | Schedule 9 (Poisons Standard) | July 8, 2011 |
| Canada | Controlled substance | Controlled Drugs and Substances Act | Listed explicitly |
| European Union | Varies by member state | No EU-wide Council Decision found | Monitored by EMCDDA; reported by Austria July 2010 |

Sources: [Ref 24, 25, 26]

---

## Clinical Trials

**No clinical trials registered on ClinicalTrials.gov for JWH-073.** A search returned zero results for "JWH-073 synthetic cannabinoid." One controlled human methodology study (Cooper et al. 2018 [Ref 29]) has established validated protocols for future controlled administration studies, but no pharmacodynamic results from human trials have been published as of the research date (May 2026).

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief for this substance.

---

## Gaps & Flags

### Safety-Critical Values Requiring Editorial Review

1. **⚠️ PARTIAL vs. FULL AGONIST FLAG:** The brief characterizes JWH-073 as a "Cannabinoid CB1 receptor partial agonist." Published primary research (Brents et al. 2012 [Ref 5]) explicitly demonstrates JWH-073 has equivalent efficacy to the full agonist CP-55,940 in GTPγS assays. Multiple additional sources (web-retrieved pharmacological supplier data [Ref 35], Ossato et al. [Ref 2]) are consistent with full agonist classification. The pharmacological class field should likely read "CB1 full agonist." This distinction matters clinically — full agonists produce more severe toxicity and faster tolerance development than partial agonists.

2. **⚠️ HALF-LIFE / TOLERANCE RESET FLAG:** Seed data states "Half-life: 5 days; Full reset: 1.5 weeks." The published elimination half-life for the primary urinary metabolite (JWH-073-COOH) is 9.3 days (range 3.6–16.8 days; Hegstad et al. 2015 [Ref 31]), with mean urine detection extending 19 days. If the 5-day figure refers to pharmacological tolerance reset rather than metabolite elimination, this value is class-inferred and unsourced — no JWH-073-specific tolerance pharmacokinetics have been published.

3. **⚠️ ACUTE AND CHRONIC TOXICITY LABEL:** The brief lists "Acute: low; Chronic: low — Inferred from pharmacological class — not sourced from literature. Review recommended." This is already flagged in the source data. Clinical evidence demonstrates severe acute toxicity in some users (seizures, acute psychosis, cardiotoxicity, multi-organ failure). "Low" may mischaracterize the acute risk. Editorial revision recommended — a more accurate characterization might be "moderate to high (acute); chronic unknown."

4. **⚠️ DOSE RANGES NOT VERIFIED IN HUMAN DATA:** The seed data's dose ranges (Light: 3–5 mg, Common: 5–10 mg, Strong: 10–15 mg smoked) are not confirmed by published controlled human studies (none exist for JWH-073). These appear to be community-derived estimates. They are plausible given the potency differential vs. JWH-018 but should be labeled as community-consensus only.

5. **⚠️ DURATION DATA NOT VERIFIED:** Onset 5–10 min, peak 60–90 min, total 1–2 hours — plausible for smoked cannabinoid but not confirmed by any published human pharmacokinetic study of JWH-073. Community-consensus-only label is appropriate.

### Data Gaps (Not Verifiable from Published Literature)

- No published controlled human pharmacokinetic study for JWH-073 (only methodology paper)
- No LD50 or therapeutic index published for JWH-073
- No published human oral bioavailability data
- No published melting point, solubility, or stability data in accessible literature
- No interaction data with classical psychedelics (LSD, DMT, mescaline), cocaine, or stimulants
- EU-wide scheduling: no Council Decision found specifically for JWH-073 (individual member states addressed this under national laws)
- No long-term chronic toxicity data in humans

### Sections Relying on Structural Analogy / Class Inference

- Duration data (onset, peak, offset): no substance-specific published data; inferred from cannabinoid class and community reports
- Tolerance timeline (5-day half-life, 1.5-week reset): cannabinoid class inference; no JWH-073-specific data
- Oral ROA effects: no published data; inferred from cannabinoid class
- Interactions with psychedelics: no data; additive psychotomimetic effects inferred from mechanism
- LD50 / acute toxicity severity rating: class inference from cannabinoid pharmacology
- CYP2C9 involvement in phase I metabolism: inferred from zebrafish model lacking CYP2C9 ortholog; not directly confirmed in human liver microsomes for JWH-073 (direct CYP phenotyping not published for JWH-073 specifically)